Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared a post on X:
“All the FDA approvals for relapsed myeloma in one slide.
20 drugs in 20 years is possible only by collaboration among industry, disease experts, patients, agencies, and foundations. Myeloma is a role model. That’s why we have mode than quadrupled the expected overall survival.”
More posts featuring Vincent Rajkumar on OncoDaily.
You Can Also Read: FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma
